Quantum Biopharma (NASDAQ:QNTM) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen cut shares of Quantum Biopharma (NASDAQ:QNTM) from a hold rating to a sell rating in a report released on Saturday morning.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Quantum Biopharma in a research report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

Quantum Biopharma Stock Performance

Shares of NASDAQ:QNTM opened at $6.18 on Friday. The firm has a market capitalization of $23.61 million, a PE ratio of -0.57 and a beta of 0.24. Quantum Biopharma has a 52-week low of $2.89 and a 52-week high of $38.25. The firm has a fifty day moving average of $8.14 and a 200 day moving average of $14.18.

Quantum Biopharma (NASDAQ:QNTM) last released its quarterly earnings results on Friday, November 7th. The company reported ($1.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($1.05). On average, sell-side analysts forecast that Quantum Biopharma will post -3.27 EPS for the current fiscal year.

Hedge Funds Weigh In On Quantum Biopharma

An institutional investor recently bought a new position in Quantum Biopharma stock. Steward Partners Investment Advisory LLC acquired a new stake in shares of Quantum Biopharma Ltd. (NASDAQ:QNTM) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,100 shares of the company’s stock, valued at approximately $63,000. Steward Partners Investment Advisory LLC owned 0.11% of Quantum Biopharma as of its most recent filing with the Securities and Exchange Commission (SEC). 1.24% of the stock is owned by institutional investors.

Quantum Biopharma Company Profile

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.